Larivière M, Beauvais B, Aziz M, Garin J F, Abeloos J, Derouin F, Bamba M, Ferly-Therizol M, Sarfati C, Basset D
Faculté de Médecine Lariboisière-Saint-Louis, Laboratoire de Parasitologie-Mycologie, Paris, France.
Bull Soc Pathol Exot Filiales. 1989 Jan;82(1):48-57.
One hundred and twenty patients out of 220 in a previous study were retreated after 6 months or one year with doses of 100, 150 or 200 mcg/kg of ivermectin. The tolerance was excellent due probably to the small number of skin microfilariae obtained with the first treatment. The annual treatment with 150 to 200 mcg/kg, better than with 100 mcg/kg, keeps for the year following the second treatment the microfilariae number between 6 and 11% of the initial level. The half-yearly administration keeps it between 1 and 7% and especially 94 to 100% of these retreated patients have a level of microfilariae less than 5 mf/mg. The results obtained with the half-yearly treatment show a considerable reduction of the number of microfilariae in the anterior chamber of the eye and the percentage of positive patients. Ivermectin is a very efficient microfilaricidal drug for the treatment of onchocerciasis and the prevention of ocular complications. Its rational use in mass campaigns should reduce, if not interrupt, the transmission of this parasitic disease.
在之前的一项研究中,220名患者中有120名在6个月或1年后接受了100、150或200微克/千克剂量的伊维菌素再次治疗。耐受性良好,这可能是由于首次治疗后获得的皮肤微丝蚴数量较少。每年使用150至200微克/千克进行治疗,效果优于100微克/千克,在第二次治疗后的一年里,微丝蚴数量保持在初始水平的6%至11%之间。半年给药一次可使其保持在1%至7%之间,特别是这些接受再次治疗的患者中有94%至100%的微丝蚴水平低于5条/毫克。半年治疗的结果显示,眼前房微丝蚴数量和阳性患者百分比大幅降低。伊维菌素是一种治疗盘尾丝虫病和预防眼部并发症的非常有效的杀微丝蚴药物。在大规模防治运动中合理使用它,即使不能阻断这种寄生虫病的传播,也应能减少其传播。